IP Library Granted Patent US 9,181,319
Granted Patent B2
US 9,181,319 · App. 14/270,736 · Granted Nov 10, 2015

Engineered nucleic acids and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,319
App. No.
14/270,736
Granted
Nov 10, 2015
Kind
B2
Abstract

Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.

Claims (16)

1. A pharmaceutical formulation comprising:

i) an effective amount of a messenger ribonucleic acid (mRNA) sequence encoding an insulin polypeptide, wherein the mRNA sequence is at least 95% identical to the sequence of SEQ ID NO: 23; and

ii) a pharmaceutically acceptable carrier,

wherein the formulation is suitable for repeated intravenous administration to a mammalian subject in need thereof.

2. The pharmaceutical formulation of claim 1 , further comprising a lipid-based transfection reagent.

3. The pharmaceutical formulation of claim 1 , wherein the effective amount of mRNA is selected from the group consisting of 100 ng, 250 ng, 500 ng, 1000 ng and 1500 ng.

4. A pharmaceutical formulation comprising:

i) an effective amount of an mRNA sequence encoding an insulin polypeptide, wherein the mRNA sequence is at least 95% identical to the sequence of SEQ ID NO: 23;

ii) a cell penetration agent; and

iii) a pharmaceutically acceptable carrier,

wherein the formulation is suitable for repeated intravenous administration to a mammalian subject in need thereof.

5. The pharmaceutical formulation of claim 4 , further comprising a lipid-based transfection reagent.

6. The pharmaceutical formulation of claim 4 , wherein the effective amount of mRNA is selected from the group consisting of 100 ng, 250 ng, 500 ng, 1000 ng and 1500 ng.

7. An mRNA sequence encoding an insulin polypeptide, wherein the mRNA sequence is at least 95% identical to the sequence of SEQ ID NO: 23.

8. The mRNA sequence of claim 7 , wherein the mRNA sequence comprises pseudouridine and 5-methyl-cytidine.

9. The mRNA sequence of claim 8 , wherein the mRNA sequence comprising pseudouridine and 5-methyl-cytidine is SEQ ID NO: 24.

Assignments (5)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
CHANGE OF NAME Recorded May 12, 2017
From: MODERNA THERAPEUTICS, INC.
To: MODERNATX, INC.
Reel/Frame 042457/0482 →
CHANGE OF NAME Recorded Oct 5, 2016
From: MODERNA THERAPEUTICS
To: MODERNATX, INC.
Reel/Frame 040233/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2014
From: SCHRUM, JASON P.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032920/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2014
From: BANCEL, STEPHANE; AFEYAN, NOUBAR B.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032900/0147 →